Iovance Biotherapeutics Inc

Latest Results (04.07.2026):

Iovance Biotherapeutics, Inc. reported fourth quarter 2025 results: Q4 product revenue of $86.8 million (~30% quarter‑over‑quarter growth) and full‑year 2025 product revenue of $263.5 million (within the $250–$300M guidance), improved gross margin (~50% in Q4), a cash position of roughly $303 million expected to fund operations into Q3 2027, and continued investment in commercial expansion (Amtagvi) and registrational clinical programs including lifileucel in NSCLC. The company posted a Q4 net loss of $71.9 million and reiterated operational initiatives to drive further margin and cost improvements.

Revenue and growth

Q4 2025 product revenue $86.8M (~30% QoQ growth). U.S. Amtagvi revenue ~$65M and global Proleukin revenue ~$22M in Q4. Full‑year 2025 product revenue $263.5M (~$264M), including ~$220M Amtagvi and ~$44M Proleukin; FY25 achieved company guidance of $250–$300M.

Gross margin and cost of sales

Q4 2025 gross margin from cost of sales ~50% (cost of sales $43.1M in Q4), reflecting execution and cost optimization; company expects additional gross margin improvements in 2026–2027 from operational initiatives.

Cash position and runway

Cash, cash equivalents, short‑term investments and restricted cash totaled about $303M as of Dec 31, 2025; the company expects this balance to fund operations into the third quarter of 2027.

Profitability and operating results

Q4 2025 net loss $71.9M (GAAP EPS loss $0.18); FY25 net loss $391.0M (EPS loss $1.09). Q4 operating expenses included R&D $71.2M and SG&A $36.4M; loss from operations in Q4 was $73.5M.

Amtagvi commercial momentum

Amtagvi drove demand and referrals with reported real‑world ORR ~44% (52% after ≤2 prior lines). Five‑year C‑144‑01 analysis showed ~31% ORR and mDOR 36+ months. Manufacturing turnaround improved to ≤32 days; Amtagvi approved in Canada with regulatory reviews underway in the UK, Australia (potential H1 2026), and Switzerland (potential H1 2027); specialty pharmacy channel introduced.

Lifileucel (IOV‑LUN‑202) — NSCLC progress

FDA granted Fast Track Designation for lifileucel in previously treated metastatic nonsquamous NSCLC. Interim data: ORR 26% and mDOR not reached at 25+ months. Company plans updated data presentation in 2026, completion of enrollment in 2026, and to support a supplemental BLA with potential launch in 2H 2027.

Pipeline and near‑term milestones

Positive early data in advanced UPS/DDLPS (50% ORR in first six evaluable patients) with a planned registrational trial in 2Q26. Progress reported in Phase 3 TILVANCE‑301 (lifileucel + pembrolizumab) and multiple Phase 1/2 programs; IND for IOV‑5001 planned H1 2026.

Operational initiatives

Iovance is internalizing lifileucel manufacturing, optimizing R&D and pursuing cost reductions; these actions are expected to reduce operating expenses and cost of sales and further improve gross margin in 2026–2027.